📊 ARDT Key Takeaways
Is Ardent Health, Inc. (ARDT) a Good Investment?
Ardent Health exhibits deteriorating operational efficiency with flat net income growth despite 6% revenue growth, coupled with negative operating cash flow of -$60.2M indicating unsustainable cash burn. Razor-thin profitability margins (2.5% net, 4.7% operating) combined with extremely poor capital returns (3% ROE, 0.8% ROA) and 39.2% EPS decline signal fundamental operational challenges that outweigh the current adequate balance sheet position.
Ardent Health shows solid top-line growth, positive net income, and strong operating cash generation, supported by a healthy liquidity position and manageable leverage. However, profitability remains thin for a hospital operator, and the sharp diluted EPS decline despite flat net income suggests weaker per-share earnings quality. The fundamentals are stable but not strong enough to justify a more aggressive rating without clearer margin expansion and sustained earnings growth.
Ardent Health, Inc. Key Strengths (ARDT)
- Solid revenue growth of 6% YoY demonstrates market demand and business continuity
- Strong liquidity position with current ratio of 2.12x and $609.7M in cash reserves
- Moderate debt/equity ratio of 0.80x provides reasonable financial flexibility
- Revenue grew 6.0% year over year while remaining profitable
- Operating cash flow of $470.51M and 7.4% FCF margin indicate solid cash generation
- Liquidity is strong with a 1.97x current ratio, 1.85x quick ratio, and $709.60M in cash
ARDT Stock Risks: Ardent Health, Inc. Investment Risks
- Critical negative operating cash flow of -$60.2M despite positive net income indicates earnings quality concerns and unsustainable operations
- Profitability deterioration with flat net income growth while revenue grew 6%, plus 39.2% EPS decline shows operational efficiency collapse
- Severely depressed returns on capital (ROE 3%, ROA 0.8%) indicate capital is being deployed inefficiently and destroying shareholder value
- Operating margin of 4.5% and net margin of 2.1% leave limited room for cost pressure or reimbursement shocks
- Diluted EPS fell 39.2% year over year even though net income was flat, pointing to weaker per-share performance
- Debt remains meaningful with $1.12B in long-term debt and 0.87x debt-to-equity
Key Metrics to Watch
- Operating Cash Flow - must return to positive territory; negative cash flow is unsustainable
- Net Income Growth - needs to accelerate above revenue growth rate to demonstrate operational improvement
- Operating Margin - current 4.7% must expand as revenue grows or the business model is broken
- Operating margin and net margin trend
- Diluted EPS growth versus net income growth
Ardent Health, Inc. (ARDT) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.12x current ratio provides a solid financial cushion.
ARDT Profit Margin, ROE & Profitability Analysis
ARDT vs Healthcare Sector: How Ardent Health, Inc. Compares
How Ardent Health, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Ardent Health, Inc. Stock Overvalued? ARDT Valuation Analysis 2026
Based on fundamental analysis, Ardent Health, Inc. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Ardent Health, Inc. Balance Sheet: ARDT Debt, Cash & Liquidity
ARDT Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Ardent Health, Inc.'s revenue has shown modest growth of 6% over the 5-year period. The most recent EPS of $0.43 reflects profitable operations.
ARDT Revenue Growth, EPS Growth & YoY Performance
ARDT Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $1.5B | $39.9M | $0.28 |
| Q3 2025 | $1.4B | -$23.5M | $-0.17 |
| Q2 2025 | $1.5B | $27.0M | $0.34 |
| Q1 2025 | $1.4B | $27.0M | $0.21 |
| Q3 2024 | $1.4B | $4.1M | $0.17 |
| Q2 2024 | $1.4B | $4.1M | $0.26 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Ardent Health, Inc. Dividends, Buybacks & Capital Allocation
ARDT SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Ardent Health, Inc. (CIK: 0001756655)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ARDT
What is the AI rating for ARDT?
Ardent Health, Inc. (ARDT) has a Combined AI Grade of C from Claude (C) and ChatGPT (B) with 74% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ARDT's key strengths?
Claude: Solid revenue growth of 6% YoY demonstrates market demand and business continuity. Strong liquidity position with current ratio of 2.12x and $609.7M in cash reserves. ChatGPT: Revenue grew 6.0% year over year while remaining profitable. Operating cash flow of $470.51M and 7.4% FCF margin indicate solid cash generation.
What are the risks of investing in ARDT?
Claude: Critical negative operating cash flow of -$60.2M despite positive net income indicates earnings quality concerns and unsustainable operations. Profitability deterioration with flat net income growth while revenue grew 6%, plus 39.2% EPS decline shows operational efficiency collapse. ChatGPT: Operating margin of 4.5% and net margin of 2.1% leave limited room for cost pressure or reimbursement shocks. Diluted EPS fell 39.2% year over year even though net income was flat, pointing to weaker per-share performance.
What is ARDT's revenue and growth?
Ardent Health, Inc. reported revenue of $1.6B.
Does ARDT pay dividends?
Ardent Health, Inc. does not currently pay dividends.
Where can I find ARDT SEC filings?
Official SEC filings for Ardent Health, Inc. (CIK: 0001756655) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ARDT's EPS?
Ardent Health, Inc. has a diluted EPS of $0.28.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is ARDT's fundamental grade?
Based on our AI fundamental analysis in June 2026, Ardent Health, Inc. has a C grade with 74% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is ARDT stock overvalued or undervalued?
Valuation metrics for ARDT: ROE of 3.0% (sector avg: 15%), net margin of 2.5% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is ARDT's AI grade for 2026?
Our dual AI analysis gives Ardent Health, Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ARDT's free cash flow?
Ardent Health, Inc.'s operating cash flow is $-60.2M, with capital expenditures of N/A. FCF margin is -3.8%.
How does ARDT compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 2.5% (avg: 12%), ROE 3.0% (avg: 15%), current ratio 2.12 (avg: 2).